Treatments and outcomes.
| n | % | |
|---|---|---|
| Immunosuppressive regimen | ||
| Methylprednisolone pulse | 20/29 | 69 |
| Prednisone, 0.5 to 1 mg/kg/d | 28/29 | 96 |
| CYC | 16/29 | 55 |
| IVIG | 8/29 | 28 |
| Plasma exchanges | 4/29 | 14 |
| MMF (first-line) | 2/29 | 7 |
| MMF (maintenance) | 10/29 | 34 |
| Outcome | ||
| Median length of stay at hospital, days (range) | 42.8 (8–227) | |
| Median followup, mos (range) | 37 (4–115) | |
| Conventional unit only | 4 | |
| ICU | 25 | |
| Death due to LM | 2 | |
| Total deaths | 3 | |
| Relapse | 1 | |
| Treatment at last visit* | ||
| Beta blockers | 5/25 | 20 |
| ACE inhibitors | 8/25 | 32 |
| HCQ | 22/25 | 88 |
| Prednisone ≤ 10 mg/d | 17/25 | 68 |
| Prednisone > 10 mg/d | 2/25 | 8 |
| MMF | 7/25 | 28 |
| AZA | 1/25 | 4 |
| MTX | 1/25 | 4 |
↵* N = 25 (3 dead, 1 lost to followup). CYC: cyclophosphamide; IVIG: intravenous immunoglobulins; ICU: intensive care unit; LM: lupus myocarditis; ACE inhibitors: angiotensin-converting enzyme inhibitors; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; AZA: azathioprine; MTX: methotrexate.